Algorithm for complementary and alternative medicine practice and research in type 2 diabetes

Journal of Alternative and Complementary Medicine

Volumn 13, Issue 1, 2007, Pages 159-175

  Bradley, Ryan ^a   Oberg, Erica B ^b   Calabrese, Carlo ^c   Standish, Leanna J ^a  

^a BASTYR UNIVERSITY   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c National College of Natural Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; ASCORBIC ACID; CARNITINE; CHROMIUM; CINNAMON EXTRACT; GYMNEMA SYLVESTRE EXTRACT; INSULIN DERIVATIVE; INSULIN SENSITIZING AGENT; OMEGA 3 FATTY ACID; THIOCTIC ACID; TRIGONELLA FOENUM GRAECUM EXTRACT; UBIDECARENONE; VANADIUM; VITAMIN D;

ALGORITHM; ALTERNATIVE MEDICINE; CLINICAL DECISION MAKING; CLINICAL PRACTICE; CLINICAL RESEARCH; CLINICAL TRIAL; DIETARY INTAKE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; MATHEMATICAL MODEL; MEDICAL LITERATURE; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITION; PANCREAS ISLET BETA CELL; PATIENT CARE; PRESCRIPTION; PRIORITY JOURNAL; PROFESSIONAL PRACTICE; REVIEW; SUPPLEMENTATION;

ALGORITHMS; ANTIOXIDANTS; COMPLEMENTARY THERAPIES; CONTROLLED CLINICAL TRIALS; DIABETES MELLITUS, TYPE 2; DIETARY SUPPLEMENTS; HUMANS; INSULIN RESISTANCE; MEDICINE, HERBAL; MINERALS; PHYTOTHERAPY; PLANTS, MEDICINAL; RESEARCH DESIGN; VITAMINS;

EID: 33847335446     PISSN: 10755535     EISSN: None     Source Type: Journal    
DOI: 10.1089/acm.2006.6207     Document Type: Review

References (196)

1. American Diabetes Association. Diabetes statistics. Online document at: www.diabetes.org/diabetes-statistics/prevalence. jsp Accessed January 25, 2007.
2. Saydeh S. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004;291:335-342.
3. Garrow D, Egede LE. Association between complementary and alternative medicine use, preventive care practices, and use of conventional medical services among adults with diabetes. Diabetes Care 2006;29:15-19.
4. Yeh G, Eisenberg DM, Kaptchuk TJ, Philips RS. Systematic review of herbs and dietary supplements for glycemic control in diabetes. Diabetes Care 2003;36:1277-1294.
5. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2006;29(suppl):s4-s42.
6. Stratton IM, Alder AI, Neil HA, et al. Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ 2000;321:405-412.
7. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetiologia 1985;28:412-419.
8. Hermans MP, Levy JC, Coppack S, et al. Comparison of the ability of 3 in vivo tests to discriminate differences in beta-cell function over the range of glucose tolerance. Diabetologia 1995;38(S2):a30.
9. Levy J, Manley S, Sutton P. Beta-cell function assessed by the hyperglycaemic clamp: Reproducibility compared with HOMA analysis from fasting values, and factors influencing variability. Abstract. Diabetes 1995;44 (suppl. 1):89A.
10. Stern SE, Williams K, Ferrannini E, et al. Identification of individuals with insulin resistance using routine clinical measurements. Diabetes 2005;54;333-339.
11. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004;27:1487-1495.
12. Bradley R, Oberg EB. Naturopathic medicine and type 2 diabetes: A retrospective analysis from an academic clinic. Alt Med Rev 2006;11:30-39.
13. Burani J, Longo PJ. Low-glycemic index carbohydrates: An effective behavioral change for glycemic control and weight management in patients with type 1 and 2 diabetes. Diabetes Educ 2006;32:78-88.
14. Riezzo G, Chiloiro M, Russo F. Functional foods: Salient features and clinical applications [review]. Curr Drug Targets Immune Endocr Metabol Disord 2005;5:331-337.
15. Surwit RS, van Tilburg MA, Zucker N, et al. Stress management improves long-term glycemic control in type 2 diabetes. Diabetes Care 2002;25:30-34.
16. Harris WS. Extending the cardiovascular benefits of omega-3 fatty acids. Curr Atheroscler Rep 2005;7:375-380.
17. Banning M. The role of omega-3-fatty acids in the prevention of cardiac events. Br J Nurs 2005;14:503-508.
18. Harrison N, Abhyankar B. The mechanism of action of omega-3 fatty acids in secondary prevention post-myocardial infarction. Curr Med Res Opin 2005;21:95-100.
19. Schmidt EB, Arneson H, de Caterina R, et al. Marine n-3 polyunsaturated fatty acids and coronary heart disease: Part I. Background, epidemiology, animal data, effects on risk factors and safety. Thromb Res 2005;115:163-170.
20. Holub DJ, Holub BJ. Omega-3 fatty acids from fish oils and cardiovascular disease. Mol Cell Biochem 2004;263:217-225.
21. Mori TA, Beilin LJ. Omega-3 fatty acids and inflammation. Curr Atheroscler Rep 2004;6:461-467.
22. Geelen A, Brouwer IA, Zock PL, Katan MB. Antiarrhythmic effects of n-3 fatty acids: Evidence from human studies. Curr Opin Lipidol 2004;15:25-30.
23. Calder PC. n-3 Fatty acids and cardiovascular disease: Evidence explained and mechanisms explored. Clin Sci (London) 2004;107:1-11.
24. Mata Lopez P, Ortega RM. Omega-3 fatty acids in the prevention and control of cardiovascular disease. Eur J Clin Nutr 2003;57(suppl1):S22-S25.
25. Richter WO. Long-chain omega-3 fatty acids from fish reduce sudden cardiac death in patients with coronary heart disease. Eur J Med Res 2003;8:332-336.
26. Kang JX, Leaf A. Prevention of fatal cardiac arrhythmias by polyunsaturated fatty acids. Am J Clin Nutr 2000;71(suppl):202S-207S.
27. Connor WE. Importance of n-3 fatty acids in health and disease. Am J Clin Nutr 2000;71(suppl.1):171S-175S.
28. Israel DH, Gorlin R. Fish oils in the prevention of atherosclerosis. J Am Coll Cardiol 1992;19:174-185.
29. Delarue J, LeFoil C, Corporeau C, Lucas D. N-3 long chain polyunsaturated fatty acids: A nutritional tool to prevent insulin resistance associated to type 2 diabetes and obesity? Reprod Nutr Dev 2004;44:289-299.
30. U.S. Food and Drug Administration (PDA). Omacor Consumer Drug Information Sheet. Bethesda: FDA, 2004.
31. Evans L. Oxidative stress and stress-activated signaling pathways: A unifying hypothesis of type 2 diabetes. Endocrine Reviews 2002;23:599-622.
32. Evans P, Halliwell B. Micronutrients: Oxidant/antioxidant status. Br J Nutr 2001;85(suppl.2:S67-S74.
33. Komosinska-Vassev K, Olczyk K, Olczyk P, Winsz-Szczotka K. Effects of metabolic control and vascular complications on indices of oxidative stress in type 2 diabetic patients. Diabetes Res Clin Pract 2005;68:207-216.
34. Tagliabue M, Pinach S, Di Bisceglie C, Brocato L. Glutathione levels in patients with erectile dysfunction, with or without diabetes mellitus. Int J Androl 2005;28:156-162.
35. Ozdemir G, Ozden M, Maral H, et al. Malondialdehyde, glutathione, glutathione peroxidase and homocysteine levels in type 2 diabetic patients with and without microalbuminuria. Ann Clin Biochem 2005;42(pt.2):99-104.
36. Eastwood MA. Interaction of dietary antioxidants in vivo: How fruit and vegetables prevent disease? QJM 1999;92:527-530.
37. Elsayed NM. Antioxidant mobilization in response to oxidative stress: A dynamic environmental-nutritional interaction. Nutrition 2001;17:828-834.
38. Nedeljkovic ZS, Gokce N, Loscalzo J. Mechanisms of oxidative stress and vascular dysfunction. Postgrad Med J 2003;79:195-199;quiz 198-200.
39. Orzechowski A. Justification for antioxidant preconditioning (or how to protect insulin-mediated actions under oxidative stress). J Biosci 2003;28:39-49.
40. Neri S, Signoreli SS, Torrisi B, et al. Effects of antioxidant supplementation on postprandial oxidative stress and endothelial dysfunction: A single-blind, 15-day clinical trial in patients with untreated type 2 diabetes, subjects with impaired glucose tolerance, and healthy controls. Clin Ther 2005;27:1764-1773.
41. Eriksson J, Kohvakka A. Magnesium and ascorbic acid supplementation in diabetes mellitus. Ann Nutr Metab 1995;39:217-223.
42. Beckman JA, Goldfine AB, Gordon MB, Creager MA. Ascorbate restores endothelium-dependent vasodilation impaired by acute hyperglycemia in humans. Circulation 2001;103:1618-1623.
43. Mullan BA, Young IS, Fee H, McCance DR. Ascorbic acid reduces blood pressure and arterial stiffness in type 2 diabetes. Hypertension 2002;40:804-809.
44. Paolisso G, Balbi V, Volpe C, et al. Metabolic benefits deriving from chronic vitamin C supplementation in aged non-insulin dependent diabetics. J Am Coll Nutr 1995;14:387-392.
45. Regensteiner JG, Popylisen S, Bauer TA, et al. Oral L-arginine and vitamins E and C improve endothelial function in women with type 2 diabetes. Vasc Med 2003;8:169-175.
46. Ting HH, Timimi FK, Boles KS, et al. Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus. J Clin Invest 1996;97:22-28.
47. Tousoulis D, Antoniades C, Tountuas, et al. Vitamin C affects thrombosis/fibrinolysis system and reactive hyperemia in patients with type 2 diabetes and coronary artery disease. Diabetes Care 2003;26:2749-2753.
48. Anderson JW, Gowri MS, Turner J, et al. Antioxidant supplementation effects on low-density lipoprotein oxidation for individuals with type 2 diabetes mellitus. J Am Coll Nutr 1999;18:451-461.
49. Darko D, Dornhorst A, Kelly FJ, et al. Lack of effect of oral vitamin C on blood pressure, oxidative stress, and endothelial function in type 2 diabetes. Clin Sci (Lond) 2002;103:339-344.
50. Lu Q, Bjorkhel L, Wretlind B, et al. Effect of ascorbic acid on microcirculation in patients with type 2 diabetes: A randomized placebo-controlled cross-over study. Clin Sci (Lond) 2005;108:507-513.
51. Gaede P, Poulsen HE, Parving HH, Pedersen O. Doubleblind, randomized study of the effect of combined treatment with vitamin C and E on albuminuria in type 2 diabetic patients. Diabet Med 2001;18:756-760.
52. Farvid MS, Jalali M, Siassi F, Hosseini M. Comparison of the effects of vitamins and/or mineral supplementation on glomerular and tubular dysfunction in type 2 diabetes. Diabetes Care 2005;28:2458-2464.
53. Mann JF, Lonn EM, Yi Q, Gerstein HC, et al. Effects of vitamin E on cardiovascular outcomes in people with mild-to-moderate renal insufficiency: Results of the HOPE study. Kidney Int 2004;65:1375-1380.
54. Miller ER, Pastor-Barriuso R, Dalal D, et al. Meta-analysis: High-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005;142:37-46.
55. Lonn E, Bosch J, Yusuf S, et al. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: A randomized controlled trial. JAMA 2005;293:1338-1347.
56. Economides PA, Khaodhiar L, Caselli A, et al. The effect of vitamin E on endothelial function of micro- and macrocirculation and left ventricular function in type 1 and type 2 diabetic patients. Diabetes 2005;54:204-211.
57. Merzouk S, Hichami A, Madani S, et al. Antioxidant status and levels of different vitamins determined by high performance liquid chromatography in diabetic subjects with multiple complications. Gen Physiol Biophys 2003;22:15-27.
58. Cheung MC, Zhao XQ, Chait A, et al. Antioxidant supplements block the response of HDL to simvastatin-niacin therapy in patients with coronary artery disease and low HDL. Arterioscler Thromb Vasc Biol 2001;21:1320-1326.
59. Barbagallo M, Dominquez LJ, Tagliamonte MR, et al. Effects of vitamin E and glutathione on glucose metabolism: Role of magnesium. Hypertension 1999;34(4pt2):1002-1006.
60. Devaraj S, Chan AV, Jialal I. Alpha-tocopherol supplementation decreases plasminogen activator inhibitor-1 and P-selectin levels in type 2 diabetic patients. Diabetes Care 2002;25:524-529.
61. Fuller CJ, Chandalia M, Garg A, et al. RRR-alpha-tocopheryl acetate supplementation at pharmacologic doses decreases low-density-lipoprotein oxidative susceptibility but not protein glycation in patients with diabetes mellitus. Am J Clin Nutr 1996 63:753-759.
62. Hirnerova E, Krahulec E, Strbova L, et al. Effect of vitamin E supplementation on microalbuminuria, lipid peroxidation, and blood prostaglandins in diabetic patients. Bratisl Lek Listy 2004;105:408-413.
63. Manning PJ, Sutherland WH, Walker RJ, et al. Effect of high-dose vitamin E on insulin resistance and associated parameters in overweight subjects. Diabetes Care 2004;27:2166-2171.
64. Paolisso G, Tagliamonte MR, Barbieri M, et al. Chronic vitamin E administration improves brachial reactivity and increases intracellular magnesium concentration in type II diabetic patients. J Clin Endocrinol Metab 2000;85:109-115.
65. Upritchard JE, Sutherland WH, Mann JL. Effect of supplementation with tomato juice, vitamin E, and vitamin C on LDL oxidation and products of inflammatory activity in type 2 diabetes. Diabetes Care 2000;23:733-738.
66. Clarke MW, Ward NC, Wu JH, et al. Supplementation with mixed tocopherols increases serum and blood cell gamma-tocopherol but does not alter biomarkers of platelet activation in subjects with type 2 diabetes. Am J Clin Nutr 2006;83:95-102.
67. Konrad D. Utilization of the insulin-signaling network in the metabolic actions of alpha-lipoic acid-reduction or oxidation? Antioxid Redox Signal 2005;7:1032-1039.
68. Evans JL, Heymann CJ, Goldfine ID, Gavin LA. Pharmacokinetics, tolerability, and fructosamine-lowering effect of a novel, controlled-release formulation of alpha-lipoic acid. Endocr Pract 2002;8:29-35.
69. Jacob S, Henricksen EJ, Schiemann AL, et al. Enhancement of glucose disposal in patients with type 2 diabetes by alpha-lipoic acid. Arzneimittelforschung 1995 45:872-874.
70. Jacob S, Ruus P, Hermann R, et al. Oral administration of RAC-alpha-lipoic acid modulates insulin sensitivity in patients with type-2 diabetes mellitus: A placebo-controlled pilot trial. Free Radic Biol Med 1999;27:309-314.
71. Haak E, Usadel KH, Kusterer K, et al. Effects of alpha-lipoic acid on microcirculation in patients with peripheral diabetic neuropathy. Exp Clin Endocrinol Diabetes 2000;108:168-174.
72. Negrisanu G, Rosu M, Bolte B, et al. Effects of 3-month treatment with the antioxidant alpha-lipoic acid in diabetic peripheral neuropathy. Rom J Intern Med 1999;37:297-306.
73. Hahm JR, Kim BJ, Kim KW. Clinical experience with thioctacid (thioctic acid) in the treatment of distal symmetric polyneuropathy in Korean diabetic patients. J Diabetes Complications 2004;18:79-85.
74. Ruhnau KJ, Meissner HP, Finn JR, et al. Effects of 3-week oral treatment with the antioxidant thioctic acid (alpha-lipoic acid) in symptomatic diabetic polyneuropathy. Diabet Med 1999;16:1040-1043.
75. Sachse G, Willms B. Efficacy of thioctic acid in the therapy of peripheral diabetic neuropathy. Horm Metab Res 1980;9(suppl):105-107.
76. Ziegler D, Gries FA. Alpha-lipoic acid in the treatment of diabetic peripheral and cardiac autonomic neuropathy. Diabetes 1997;46;(suppl.2:S62-S66.
77. Morcos M, Borcea V, Isermann B, et al. Effect of alpha-lipoic acid on the progression of endothelial cell damage and albuminuria in patients with diabetes mellitus: An exploratory study. Diabetes Res Clin Pract 2001;52:175-183.
78. Hodgson JM, Watts GF, Playford DA, et al. Coenzyme Q10 improves blood pressure and glycaemic control: A controlled trial in subjects with type 2 diabetes. Eur J Clin Nutr 2002;56:1137-1142.
79. Burke BE, Neuenschwander R, Olson RD. Randomized, double-blind, placebo-controlled trial of coenzyme Q10 in isolated systolic hypertension. South Med J 2001;94:1112-1117.
80. Langsjoen P, Langsjoen P, Willis R, Folkers K. Treatment of essential hypertension with coenzyme Q10. Mol Aspects Med 1994;15:(suppl):S265-S272.
81. Oda T. Recovery of load-induced left ventricular diastolic dysfunction by coenzyme Q10: Echocardiographic study. Mol Aspects Med 1994;15:(suppl):S149- S154.
82. Miyake Y, Shouzu, Nishikawa M, et al. Effect of treatment with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on serum coenzyme Q10 in diabetic patients. Arzneimittelforschung 1999;49:324-329.
83. Hargreaves IP, Duncan AJ, Heales SJ, Land JM. The effect of HMG-CoA reductase inhibitors on coenzyme Q10: Possible biochemical/clinical implications. Drug Saf 2005;28:659-676.
84. Bargossi AM, Grossi G, Battino M, et al. Exogenous CoQ10 supplementation prevents plasma ubiquinone reduction induced by HMG-CoA reductase inhibitors. Mol Aspects Med 1994;15:(suppl):S187-S193.
85. James JS. Stanford NAC study: Glutathione level predicts survival. AIDS Treat News 1997;266:1-5.
86. James LP, Mayeux PR, Hinson JA. Acetaminophen-induced hepatotoxicity. Drug Metab Dispos 2003;31:1499-1506.
87. De Rosa SC, Zaretsky MD, Dubs JG, et al. N-acetylcysteine replenishes glutathione in HIV infection. Eur J Clin Invest 2000;30:915-929.
88. Skrzydlewska E, Farbiszewski R. Protective effect of N-acetylcysteine on reduced glutathione, reduced glutathione-related enzymes and lipid peroxidation in methanol intoxication. Drug Alcohol Depend 1999;57:61-67.
89. Fulghesu AM, Clampella M, Muzj G, Belosi C, et al. N-acetyl-cysteine treatment improves insulin sensitivity in women with polycystic ovary syndrome. Fertil Steril 2002;77:1128-1135.
90. De Mattia G, Bravi MK, Laurenti O, et al. Reduction of oxidative stress by oral N-acetyl-L-cysteine treatment decreases plasma soluble vascular cell adhesion molecule-1 concentrations in non-obese, non-dyslipidaemic, normotensive, patients with non-insulin-dependent diabetes. Diabetologia 1998;41:1392-1396.
91. Ivanovski O, Szumilak D, Mguyen-Khoa T, et al. The antioxidant N-acetylcysteine prevents accelerated atherosclerosis in uremic apolipoprotein E knockout mice. Kidney Int 2005;67:2288-2294.
92. Tossios P, Bloch W, Huebner A, et al. N-acetylcysteine prevents reactive oxygen species-mediated myocardial stress in patients undergoing cardiac surgery: Results of a randomized, double-blind, placebo-controlled clinical trial. J Thorac Cardiovasc Surg 2003;126:1513-1520.
93. Aviram M, Rosenblat M, Gaitini D, et al. Pomegranate juice consumption for 3 years by patients with carotid artery stenosis reduces common carotid intima-media thickness, blood pressure, and LDL oxidation. Clin Nutr 2004;23:423-433.
94. Esmaillzadeh A, Tahbaz F, Gaieni I, et al. Concentrated pomegranate juice improves lipid profiles in diabetic patients with hyperlipidemia. J Med Food 2004;7:305-308.
95. Fuhrman B, Volkova N, Aviram M. Pomegranate juice inhibits oxidized LDL uptake and cholesterol biosynthesis in macrophages. J Nutr Biochem 2005;16:570-576.
96. Kaplan M, Hayek T, Raz A, et al. Pomegranate juice supplementation to atherosclerotic mice reduces macrophage lipid peroxidation, cellular cholesterol accumulation, and development of atherosclerosis. J Nutr 2001;131:2082-2089.
97. Dwyer JH, Paul-Labrador MJ, Fan J, et al. Progression of carotid intima-media thickness and plasma antioxidants: The Los Angeles atherosclerosis study. Arterioscler Thromb Vasc Biol 2004;24:313-319.
98. Koh HH, Murray U, Nolan D, et al. Plasma and macular responses to lutein supplement in subjects with and without age-related maculopathy: A pilot study. Exp Eye Res 2004;79:21-27.
99. Richer S, Stiles W, Statkote L, et al. Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: The Veterans LAST study (Lutein Antioxidant Supplementation Trial). Optometry 2004;75:216-230.
100. Gale CR, Hall NF, Phillips DI, Martyn CN. Lutein and zeaxanthin status and risk of age-related macular degeneration. Invest Ophthalmol Vis Sci 2003;44:2461-2465.
101. Bone RA, Landrum JT, Guerra LH, Ruiz CA. Lutein and zeaxanthin dietary supplements raise macular pigment density and serum concentrations of these carotenoids in humans. J Nutr 2003;133:992-998.
102. Flood V, Smith W, Wang JJ, et al. Dietary antioxidant intake and incidence of early age-related maculopathy: The Blue Mountains Eye Study. Ophthalmology 2002;109:2272-2278.
103. Rizvi SI, Zaid MA, Anis R, Mishra N. Protective role of tea catechins against oxidation-induced damage of type 2 diabetic erythrocytes. Clin Exp Pharmacol Physiol 2005;32(1-2):70-75.
104. Ludwig A, Lorenz M, Grimbo N, et al. The tea flavonoid epigallocatechin-3-gallate reduces cytokine-induced VCAM-1 expression and monocyte adhesion to endothelial cells. Biochem Biophys Res Commun 2004;316:659-665.
105. Crouvezier S, Powell B, Keir D, Yagoob P. The effects of phenolic components of tea on the production of pro- and anti-inflammatory cytokines by human leukocytes in vitro. Cytokine 2001;13:280-286.
106. Kent JW, Comuzzie AG, Mahaney MC, et al. Intercellular adhesion molecule-1 concentration is genetically correlated with insulin resistance, obesity, and HDL concentration in Mexican Americans. Diabetes 2004;53:2691-2695.
107. Schwedhelm E, Mass R, Troost R, Boger RH. Clinical pharmacokinetics of antioxidants and their impact on systemic oxidative stress. Clin Pharmacokinet 2003;42:437-459.
108. Carroll MF, Schade DS. Timing of antioxidant vitamin ingestion alters postprandial proatherogenic serum markers. Circulation 2003;108:24-31.
109. Anderson RA. Chromium as an essential nutrient for humans. Regul Toxicol Pharmacol 1997;26(1pt2:S35-S41.
110. Anderson RA. Chromium in the prevention and control of digestion Diabetes Metab 2000;26:22-27.
111. Anderson RA. Chromium and insulin resistance. Nutrition Research Reviews 2003;16:267-275.
112. Morris BW, MacNeil S, Hardisty CA, et al. Chromium homeostasis in patients with type II (NIDDM) diabetes. J Trace Elem Med Biol 1999;13:57-61.
113. Davis CM, Vincent JB. Chromium oligopeptide activates insulin receptor tyrosine kinase activity. Biochemistry. Biochemistry 1997;36:4382-4385.
114. Abraham AS, Brooks BA, Eylath U. The effects of chromium supplementation on serum glucose and lipids in patients with and without non-insulin-dependent diabetes. Metabolism 1992;41:768-771.
115. Anderson RA, Cheng N, Bryden NA, et al. Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes. Diabetes 1997;46:1786-1791.
116. Anderson RA. Potential antioxidant effects of zinc and chromium supplementation in people with type 2 diabetes mellitus. J Am Coll Nutr 2001;20:212-218.
117. Bahijiri SM, Mira SA, Mufti AM, Ajabnoor MA. The effects of inorganic chromium and brewer's yeast supplementation on glucose tolerance, serum lipids and drug dosage in individuals with type 2 diabetes. Saudi Med J 2000;21:831-837.
118. Bahijri SM, Mufti AM. Beneficial effects of chromium in people with type 2 diabetes, and urinary chromium response to glucose load as a possible indicator of status. Biol Trace Elem Res 2002;85:97-109.
119. Ghosh D, Bhattacharya B, Mukherjee B, et al. Role of chromium supplementation in Indians with type 2 diabetes mellitus. J Nutr Biochem 2002;13:690-697.
120. Lee NA, Reasner CA. Beneficial effect of chromium supplementation on serum triglyceride levels in NIDDM. Diabetes Care 1994;17:1449-1452.
121. Rabinovitz MB. Effect of chromium supplementation on blood glucose and lipid levels in type 2 diabetes mellitus elderly patients. Int J Vitam Nutr Res 2004;74:178-182.
122. Thomas VL, Gropper SS. Effect of chromium nicotinic acid supplementation on selected cardiovascular disease risk factors. Biol Trace Elem Res 1996;55:297-305.
123. Uusitupa MI, Kumpulainen JT, Voutilainen E, et al. Effect of inorganic chromium supplementation on glucose tolerance, insulin response, and serum lipids in noninsulin-dependent diabetics. Am J Clin Nutr 1983;38:404-410.
124. Elias AN, Grossman M, Valenta LJ. Use of the artificial beta cell (ABC) in the assessment of peripheral insulin sensitivity: Effect of chromium supplementation in diabetic patients. J Gen Pharmacol 1984;15:535-539.
125. Kleefstra N, Houweling ST, Jansman FG, et al. Chromium treatment has no effect in patients with poorly controlled, insulin-treated type 2 diabetes in an obese Western population: A randomized, double-blind, placebo-controlled trial. Diabetes Care 2006;29:521-525.
126. de Valk HW. Magnesium in diabetes mellitus. Neth J Med 1999;54:139-146.
127. de Lourdes Lima M, Cruz T, Pousada JC, et al. The effect of magnesium supplementation in increasing doses on the control of type 2 diabetes. Diabetes Care 1998;21:682-686.
128. Takaya J, Higashino H, Kobayashi Y. Intracellular magnesium and insulin resistance. Magnes Res 2004;17:126-136.
129. Paolisso G, Passaiello N, Pizza G, et al. Dietary magnesium supplements improve B-cell response to glucose and arginine in elderly non-insulin dependent diabetic subjects. Acta Endocrinol (Copenh) 1989;121:16-20.
130. Yajnik CS, Smith RF, Hackaday TD, Ward NI. Fasting plasma magnesium concentrations and glucose disposal in diabetes Br Med J (Clin Res Ed) 1984;288:1032-1034.
131. Rodriguez-Moran M, Guerrero-Romero F. Oral magnesium supplementation improves insulin sensitivity and metabolic control in type 2 diabetic subjects: A randomized double-blind controlled trial. Diabetes Care 2003;26:1147-1152.
132. de Valk HW, Verkaaik R, van Rijn HJ, et al. Oral magnesium supplementation in insulin-requiring type 2 diabetic patients. Diabet Med 1998;15:503-507.
133. Eibl NL, Kopp HP, Nowak HR, et al. Hypomagnesemia in type 2 diabetes: Effect of a 3-month replacement therapy. Diabetes Care 1995;18:188-192.
134. Purvis JR, Cummings DM, Landsman P, et al. Effect of oral magnesium supplementation on selected cardiovascular risk factors in non-insulin-dependent diabetics. Arch Fam Med 1994;3:503-508.
135. Gullestad L, Jacobsen T, Dolva LO. Effect of magnesium treatment on glycemic control and metabolic parameters in NIDDM patients. Diabetes Care 1994;17:460-461.
136. Corica F, Allegra A, DiBenedetto A, et al. Effects of oral magnesium supplementation on plasma lipid concentrations in patients with non-insulin-dependent diabetes mellitus. Magnes Res 1994;7:43-47.
137. Paolisso G, Sgambato S, Pizza G, Passariello N, et al. Improved insulin response and action by chronic magnesium administration in aged NIDDM subjects. Diabetes Care 1989;12:265-269.
138. Boden G, Chen X, Ruiz J, et al. Effects of vanadyl sulfate on carbohydrate and lipid metabolism in patients with non-insulin-dependent diabetes mellitus. Metabolism 1996;45:1130-1135.
139. Cohen N, Halberstam M, Shilmovich P, et al. Oral vanadyl sulfate improves hepatic and peripheral insulin sensitivity in patients with non-insulin-dependent diabetes mellitus. J Clin Invest 1995;95:2501-2509.
140. Cusi K, Cukier S, DeFronza RA, et al. Vanadyl sulfate improves hepatic and muscle insulin sensitivity in type 2 diabetes. J Clin Endocrinol Metab 2001;86:1410-1417.
141. Goldfine AB, Patti ME, Zuberi L, et al. Metabolic effects of vanadyl sulfate in humans with non-insulin-dependent diabetes mellitus: In vivo and in vitro studies. Metabolism 2000;49:400-410.
142. Halberstam M, Cohen N, Shlimovich P, et al. Oral vanadyl sulfate improves insulin sensitivity in NIDDM but not in obese nondiabetic subjects. Diabetes 1996;45:659-666.
143. Mang B, Wolters M, Schmitt B, et al. Effects of a cinnamon extract on plasma glucose, HbA, and serum lipids in diabetes mellitus type 2. Eur J Clin Invest 2006;36:340-344.
144. Vanschoonbeek K, Thomassen BJ, Senden JM, et al. Cinnabetes supplementation does not improve glycemic control in postmenopausal type 2 diabetes patients. J Nutr 2006;136:977-980.
145. Khan A, Safdar M, Ali Khan MM, et al. Cinnamon improves glucose and lipids of people with type 2 diabetes. Diabetes Care 2003;26:3215-3218.
146. Imparl-Radosevich J, Deas S, Polansky MM, et al. Regulation of PTP-1 and insulin receptor kinase by fractions from cinnamon: Implications for cinnamon regulation of insulin signalling. Horm Res 1998;50:177-182.
147. Anderson RA, Broadhurst CL, Polansky MM, et al. Isolation and characterization of polyphenol type-A polymers from cinnamon with insulin-like biological activity. J Agric Food Chem 2004;52:65-70.
148. Jogl G, Hsiao YS, Tong L. Structure and function of carnitine acyltransferases. Ann N Y Acad Sci 2004;1033:17-29.
149. Peluso G, Petillo O, Margarucci S, Mingrone G, et al. Decreased mitochondrial carnitine translocase in skeletal muscles impairs utilization of fatty acids in insulin-resistant patients. Front Biosci 2002;7:a09-a1l6.
150. Dubois M, Kerr-Conte J, Gmyr V, et al. Non-esterified fatty acids are deleterious for human pancreatic islet function at physiological glucose concentration. Diabetologia 2004;47:463-469.
151. Shankar SS, Mirzamohammadi B, Walsh JB, Steinberg HO. L-Carnitine may attenuate free fatty acid-induced endothelial dysfunction. Ann N Y Acad Sci 2004;1033:189-197.
152. De Gaetano A, Mingrone G, Castagneto M, Calvani M. Carnitine increases glucose disposal in humans. J Am Coll Nutr 1999;18:289-295.
153. Giancaterini A, De Gaetano A, Mingrone G, et al. Acetyl-L-carnitine infusion increases glucose disposal in type 2 diabetic patients. Metabolism 2000;49:704-708.
154. Rahbar AR, Shakerhosseini R, Saadat N, et al. Effect of L-carnitine on plasma glycemic and lipidemic profile in patients with type 2 diabetes mellitus. Eur J Clin Nutr 2005;59:592-596.
155. Rebouche CJ. Kinetics, pharmacokinetics, and regulation of L-carnitine and acetyl-L-carnitine metabolism. Ann N Y Acad Sci 2004;1033:30-41.
156. Soneru IL, Khan T, Orfalian Z, Abraira C. Acetyl-L-carnitine effects on nerve conduction and glycemic regulation in experimental diabetes. Endocr Res 1997;23:27-36.
157. Sima AA, Calvani M, Mehra M, et al. Acetyl-L-carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: An analysis of two randomized placebo-controlled trials. Diabetes Care 2005;28:89-94.
158. De Grandis D, Minardi C. Acetyl-L-carnitine (levacecarnine) in the treatment of diabetic neuropathy: A long-term, randomized, double-blind, placebo-controlled study. Drugs R D 2002;3:223-331.
159. Madar Z, Abel R, Samish S, Arad J. Glucose-lowering effect of fenugreek in non-insulin dependent diabetics. Eur J Clin Nutr 1988;42:51-54.
160. Gupta A, Gupta R, Lal B. Effect of Trigonella foenum-graecum (fenugreek) seeds on glycemic control and insulin resistance in type 2 diabetes mellitus: A double blind placebo controlled study. J Assoc Physicians India 2001;49:1057-1061.
161. Mondal DK, Yousef BM, Banu LA, et al. Effect of fenugreek seeds on the fasting blood glucose level in the streptozotocin induced diabetic rats. Mymensingh Med J 2004;13:161-164.
162. Hannan JM, Rokeya BM, Faruque O, et al. Effect of soluble dietary fiber fraction of Trigonella foenum graecum on glycemic, insulinemic, lipidemic and platelet aggregation status of type 2 diabetic model rats. J Ethnopharmacol 2003;88:73-77.
163. Vats V, Padav SP, Grover JK. Effect of T. foenum graecum on glycogen content of tissues and the key enzymes of carbohydrate metabolism. J Ethnopharmacol 2003;85:237-242.
164. Vijayakumar MV, Singh S, Chhipa RR, Bhat MK. The hypoglycaemic activity of fenugreek seed extract is mediated through the stimulation of an insulin signalling pathway. Br J Pharmacol 2005;146:41-48.
165. Hirsch IB, Brownlee M. Should minimal blood glucose variability become the gold standard of glycemic control? J Diabetes Complications 2005;19:178-181.
166. Robertson RP, Harmon J, Tan PO, et al. Glucose toxicity in beta-cells: Type 2 diabetes, good radicals gone bad, and the glutathione connection. Diabetes 2003;52:581-587.
167. Ho E, Bray TM. Antioxidants, NFkappaB activation, and diabetogenesis. Proc Soc Exp Biol Med 1999;222:205-213.
168. Mathieu C, Gysemans C, Giulietti A, Bouillon R. Vitamin D and diabetes. Diabetologia 2005;48:1247-1257.
169. Chie KC, Chu, Go VL, Saad MF. Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am J Clin Nutr 2004;79:820-825.
170. Heaney RP. Functional indices of vitamin D status and ramifications of vitamin D deficiency. Am J Clin Nutr 2004;80(6suppl):1706S-1709S.
171. Vieth R. Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. Am J Clin Nutr 1999;69:842-856.
172. 3 on insulin secretion and peripheral insulin sensitivity in type 2 diabetic patients. Int J Clin Pract 2003;57:258-261.
173. Orwoll E, Riddle M, Prince M. Effects of vitamin D on insulin and glucagon secretion in non-insulin-dependent diabetes mellitus. Am J Clin Nutr 1994;59:1083-1087.
174. Kumar S, Davies M, Zakaria Y, et al. Improvement in glucose tolerance and beta-cell function in a patient with vitamin D deficiency during treatment with vitamin D. Postgrad Med J 1994;70:440-443.
175. Taylor AV, Wise PH. Vitamin D replacement in Asians with diabetes may increase insulin resistance. Postgrad Med J 1998;74:365-366.
176. Zeitz U, Weber K, Soegiarto DW, et al. Impaired insulin secretory capacity in mice lacking a functional vitamin D receptor. FASEB J 2003;17:509-511.
177. Ayesha I, Bala TS, Reddy CV, Raghuramulu N. Vitamin D deficiency reduces insulin secretion and turnover in rats. Diabetes Nutr Metab 2001;14:78-84.
178. 3 deficiency and alterations of glucose metabolism in rat endocrine pancreas. Diabetes Metab 1998;24:344-350.
179. 3 on pancreatic islet insulin release via the cyclic AMP pathway in the rat. Br J Pharmacol 1997;121:751-758.
180. Baskaran K, Kizar Ahamath B, Rhadha Shanmugasundaram K, Shanmugasundaram ER. Antidiabetic effect of a leaf extract from Gymnema sylvestre in non-insulin-dependent diabetes mellitus patients. J Ethnopharmacol 1990;30:295-300.
181. Shanmugasundaram ER, Rajesawi G, Baskaran K, et al. Use of Gymnema sylvestre leaf extract in the control of blood glucose in insulin-dependent
182. Shanmugasundaram ER, Gopinath KL, Radha Shanmugasundaram K, Rajendran VM. Possible regeneration of the islets of Langerhans in streptozotocin-diabetic rats given Gymnema sylvestre leaf extracts. J Ethnopharmacol 1990;30:265-279.
183. Persaud SJ, Al-Majed H, Raman A, Jones PM. Gymnema sylvestre stimulates insulin release in vitro by increased membrane permeability. J Endocrinol 1999;163:207-212.
184. Vuksan V, Sievenpiper JL. Herbal remedies in the management of diabetes: Lessons learned from the study of ginseng. Nutr Metab Cardiovasc Dis 2005;15:149-160.
185. Vuksan V, Sievenpiper JL, Wong J, Xu Z, et al. American ginseng (Panax quinquefolius L.) attenuates postprandial glycemia in a time-dependent but not dose-dependent manner in healthy individuals. Am J Clin Nutr 2001;73:753-758.
186. Vuksan V, Stavro MP, Sievenpiper JL, et al. Similar post-prandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes. Diabetes Care 2000;23:1221-1226.
187. Vuksan V, Sievenpiper JL, Koo VY, et al. American ginseng (Panax quinquefolius L.) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus. Arch Intern Med 2000;160:1009-1013.
188. Sotaniemi EA, Haapakoski E, Rautio A. Ginseng therapy in non-insulin-dependent diabetic patients. Diabetes Care 1995;18:1373-1375.
189. Rotshteyn Y, Zito SW. Application of modified in vitro screening procedure for identifying herbals possessing sulfonylurea-like activity. J Ethnopharmacol 2004;93(2-3):337-344.
190. Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V. Decreasing, null and increasing effects of eight popular types of ginseng on acute postprandial glycemic indices in healthy humans: The role of ginsenosides. J Am Coll Nutr 2004;23:248-258.
191. Sievenpiper JL, Arnason JT, et al. Null and opposing effects of Asian ginseng (Panax ginseng C.A. Meyer) on acute glycemia: Results of two acute dose escalation studies. J Am Coll Nutr 2003;22:524-532.
192. Sievenpiper JL, Amason JT, Leiter LA, Vuksan V. Variable effects of American ginseng: A batch of American ginseng (Panax quinquefolius L.) with a depressed ginsenoside profile does not affect postprandial glycemia. Eur J Clin Nutr 2003;57:243-248.
193. Vuksan V, Sievenpiper JL, Xu Z, et al. Konjac-Mannan and American ginseng: Emerging alternative therapies for type 2 diabetes mellitus. J Am Coll Nutr 2001;20(5suppl):370S-380S;discussion 381S-383S.
194. Vuksan V, Xu Z, Jenkins AL, et al. American Ginseng improves long term glycemic control in Type 2 diabetes: Double-blind placebo controlled crossover trial. American Diabetes Association Annual Meeting, Diabetes 2000;Suppl 1 A95: abstr 384.
195. American Diabetes Association. Direct and Indirect Costs of Diabetes in the United States. Online document at: www.diabetes.org/diabetes-statistics/ cost-of-diabetes-in-US.jsp Accessed January 25, 2007.
196. Institute of Medicine. Complementary and Alternative Medicine in the United States, 1st ed. Washington, DC: National Academy Press. 2005:337.